102 related articles for article (PubMed ID: 11140321)
1. [Recent progress in radionuclide therapy].
Kasagi K; Iwata M; Misaki T; Konishi J; Sakahara H
Nihon Igaku Hoshasen Gakkai Zasshi; 2000 Nov; 60(13):729-37. PubMed ID: 11140321
[TBL] [Abstract][Full Text] [Related]
2. [Internal radiation therapy for malignant neoplasm].
Yokoyama K; Kinuya S; Tonami N
Gan To Kagaku Ryoho; 1999 May; 26(6):768-74. PubMed ID: 10410145
[TBL] [Abstract][Full Text] [Related]
3. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
Schlumberger M; Challeton C; De Vathaire F; Travagli JP; Gardet P; Lumbroso JD; Francese C; Fontaine F; Ricard M; Parmentier C
J Nucl Med; 1996 Apr; 37(4):598-605. PubMed ID: 8691248
[TBL] [Abstract][Full Text] [Related]
4. [Results of radioiodine therapy in 47 patients with distant metastases of differentiated thyroid carcinoma].
Miyamoto S; Kasagi K; Endo K; Iida Y; Hidaka A; Hatabu H; Konishi J
Nihon Igaku Hoshasen Gakkai Zasshi; 1991 Jul; 51(7):810-21. PubMed ID: 1891347
[TBL] [Abstract][Full Text] [Related]
5. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of [131]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma.
Colombo L; Lomuscio G; Vignati A; Dottorini ME
J Nucl Biol Med (1991); 1991; 35(4):300-4. PubMed ID: 1823841
[TBL] [Abstract][Full Text] [Related]
9. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
10. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
[TBL] [Abstract][Full Text] [Related]
11. [Results of treatment of Graves-Basedow disease with 131I at low calculated doses].
Gómez Arnaiz N; Gómez Saez JM; Orti Llavería A; Gavaldá Mestre L; Mairal Pairó L; Soler Ramón J
Rev Clin Esp; 1998 Feb; 198(2):57-60. PubMed ID: 9558917
[TBL] [Abstract][Full Text] [Related]
12. [131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.
Hoefnagel CA; Schornagel J; Valdés Olmos RA
J Nucl Biol Med (1991); 1991; 35(4):308-12. PubMed ID: 1823843
[TBL] [Abstract][Full Text] [Related]
13. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
14. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
[TBL] [Abstract][Full Text] [Related]
15. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
Grünwald F; Menzel C; Fimmers R; Zamora PO; Biersack HJ
J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
[TBL] [Abstract][Full Text] [Related]
17. Hierarchy of treatment variables affecting outcome of 131I therapy in thyroid cancer patients with lung metastases.
Kozak OV; Sukach GG; Korchinskaya OI; Trembach AM; Turicina VL; Voit NU
Exp Oncol; 2005 Jun; 27(2):150-5. PubMed ID: 15995635
[TBL] [Abstract][Full Text] [Related]
18. Place of meta-[131I]iodobenzylguanidine in the treatment of neuroblastoma: the Genoa experience.
Garaventa A; Pianca C; Conte M; Nigro M; De Bernardi B; Claudiani F; Stimamiglio P; Bertolazzi L; Cabria M; Villavecchia GP
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):58-60. PubMed ID: 9002751
[TBL] [Abstract][Full Text] [Related]
19. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients.
Dottorini ME; Vignati A; Mazzucchelli L; Lomuscio G; Colombo L
J Nucl Med; 1997 May; 38(5):669-75. PubMed ID: 9170425
[TBL] [Abstract][Full Text] [Related]
20. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
